{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:35:53Z","timestamp":1759962953726},"reference-count":43,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.intimp.2014.03.017","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T12:45:12Z","timestamp":1397393112000},"page":"370-376","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A monoclonal antibody ameliorates local inflammation and osteoporosis by targeting TNF-\u03b1 and RANKL"],"prefix":"10.1016","volume":"20","author":[{"given":"Hongyan","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xulong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2014.03.017_bb0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.intimp.2014.03.017_bb0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.autrev.2008.11.003","article-title":"Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.intimp.2014.03.017_bb0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.intimp.2014.03.017_bb0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinthera.2012.02.002","article-title":"Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data","volume":"34","author":"Dempster","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.intimp.2014.03.017_bb0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.intimp.2014.03.017_bb0030","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbrc.2006.06.098","article-title":"Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody","volume":"347","author":"Kamijo","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.intimp.2014.03.017_bb0035","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1186\/ar2879","article-title":"RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies","volume":"11","author":"Stolina","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.intimp.2014.03.017_bb0040","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1016\/j.biomaterials.2012.07.047","article-title":"Therapeutic role of a vaccine targeting RANKL and TNF-alpha on collagen-induced arthritis","volume":"33","author":"Yuan","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2014.03.017_bb0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI13890","article-title":"Crystal structure of the TRANCE\/RANKL cytokine reveals determinants of receptor\u2013ligand specificity","volume":"108","author":"Lam","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.intimp.2014.03.017_bb0050","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1074\/jbc.M707933200","article-title":"Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist","volume":"283","author":"Shibata","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2014.03.017_bb0055","doi-asserted-by":"crossref","first-page":"20281","DOI":"10.1073\/pnas.1011686107","article-title":"Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis","volume":"107","author":"Ta","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.intimp.2014.03.017_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.actatropica.2012.11.001","article-title":"Production and characterization of a monoclonal antibody against recombinant saposin-like protein 2 of Fasciola gigantica","volume":"125","author":"Kueakhai","year":"2013","journal-title":"Acta Trop"},{"key":"10.1016\/j.intimp.2014.03.017_bb0065","doi-asserted-by":"crossref","unstructured":"Winzeler A, Wang JT. Culturing hybridoma cell lines for monoclonal antibody production. Cold Spring Harb Protoc 2013;640\u20132.","DOI":"10.1101\/pdb.prot074914"},{"key":"10.1016\/j.intimp.2014.03.017_bb0070","unstructured":"National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies. Monoclonal antibody production. Washington, DC: National Academies Press (US); 1999."},{"key":"10.1016\/j.intimp.2014.03.017_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1006\/cyto.1998.0492","article-title":"Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents","volume":"11","author":"Humphreys","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2014.03.017_bb0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jim.2010.12.015","article-title":"Flow cytometric mast cell-mediated cytotoxicity assay: a three-color flow cytometric approach using monoclonal antibody staining with annexin V\/propidium iodide co-labeling to assess human mast cell-mediated cytotoxicity by fluorosphere-adjusted counts","volume":"365","author":"Ozdemir","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.intimp.2014.03.017_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2005.02143.x","article-title":"The intriguing biology of the tumour necrosis factor\/tumour necrosis factor receptor superfamily: players, rules and the games","volume":"115","author":"Hehlgans","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2014.03.017_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2012.02.026","article-title":"Kim do K et al. Arctigenin suppresses receptor activator of nuclear factor kappaB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages","volume":"682","author":"Kim","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.intimp.2014.03.017_bb0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2014.03.017_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.17305\/bjbms.2013.2339","article-title":"Bix01294 suppresses osteoclast differentiation on mouse macrophage-like raw264.7 cells","volume":"13","author":"Tsuda","year":"2013","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.intimp.2014.03.017_bb0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10753-011-9364-y","article-title":"Protective effects of radon inhalation on carrageenan-induced inflammatory paw edema in mice","volume":"35","author":"Kataoka","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2014.03.017_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-9255-9-2","article-title":"Anti-inflammation effects of hydrogen saline in LPS activated macrophages and carrageenan induced paw oedema","volume":"9","author":"Xu","year":"2012","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.intimp.2014.03.017_bb0115","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1210\/en.2008-0150","article-title":"Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor","volume":"149","author":"Idris","year":"2008","journal-title":"Endocrinology"},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2014.03.017_bb0120","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1007\/s00198-005-1859-7","article-title":"Animal models for fracture treatment in osteoporosis","volume":"16","author":"Egermann","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.intimp.2014.03.017_bb0125","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1359\/JBMR.050307","article-title":"Ovariectomy-induced bone loss varies among inbred strains of mice","volume":"20","author":"Bouxsein","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.intimp.2014.03.017_bb0130","doi-asserted-by":"crossref","first-page":"29851","DOI":"10.1074\/jbc.M112.377945","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss","volume":"287","author":"Onal","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2014.03.017_bb0135","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1359\/jbmr.040119","article-title":"In vivo inhibition of osteoblastic metalloproteinases leads to increased trabecular bone mass","volume":"19","author":"Geoffroy","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.intimp.2014.03.017_bb0140","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units","volume":"2","author":"Parfitt","year":"1987","journal-title":"Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res"},{"key":"10.1016\/j.intimp.2014.03.017_bb0145","first-page":"89","article-title":"Treatment of rheumatoid arthritis patients with anti-TNF-alpha monoclonal antibody is accompanied by down-regulation of the activating Fcgamma receptor I on monocytes","volume":"26","author":"Wijngaarden","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.intimp.2014.03.017_bb0150","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.60.7.660","article-title":"Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis","volume":"60","author":"Barrera","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.03.017_bb0155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cytogfr.2007.04.002","article-title":"How TNF, was recognized as a key mechanism of disease","volume":"18","author":"Clark","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.intimp.2014.03.017_bb0160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejphar.2009.10.036","article-title":"Anti-inflammatory activity of hispidol A 25-methyl ether, a triterpenoid isolated from Ponciri Immaturus Fructus","volume":"627","author":"Shin","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.intimp.2014.03.017_bb0165","doi-asserted-by":"crossref","first-page":"478246","DOI":"10.1093\/ecam\/nep027","article-title":"Analgesic effects and the mechanisms of anti-inflammation of hispolon in mice","volume":"2011","author":"Chang","year":"2011","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.intimp.2014.03.017_bb0170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cyto.2011.11.014","article-title":"Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha\/IL-1 or LIGHT","volume":"57","author":"Mabilleau","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2014.03.017_bb0175","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.intimp.2014.03.017_bb0180","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1073\/pnas.200294797","article-title":"Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene","volume":"97","author":"Kim","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.intimp.2014.03.017_bb0185","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","article-title":"The molecular understanding of osteoclast differentiation","volume":"40","author":"Asagiri","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.intimp.2014.03.017_bb0190","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","article-title":"TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis","volume":"159","author":"Pettit","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.intimp.2014.03.017_bb0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1543-2912(13)60114-9","article-title":"Denosumab (AMG 162), a fully human monoclonal antibody against RANK ligand activity","volume":"3","author":"Reddy","year":"2005","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.intimp.2014.03.017_bb0200","doi-asserted-by":"crossref","unstructured":"Dore RK. The RANKL pathway and denosumab. Rheum Dis Clin North Am 2011;37:433\u201352, vi-vii.","DOI":"10.1016\/j.rdc.2011.07.004"},{"key":"10.1016\/j.intimp.2014.03.017_bb0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","article-title":"Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"49","author":"Kostenuik","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.intimp.2014.03.017_bb0210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.molmed.2008.04.001","article-title":"Molecular mechanisms of inflammatory bone damage: emerging targets for therapy","volume":"14","author":"Herman","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.intimp.2014.03.017_bb0215","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S8756-3282(01)00682-2","article-title":"Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis","volume":"30","author":"Romas","year":"2002","journal-title":"Bone"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914001209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914001209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T13:34:14Z","timestamp":1565357654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576914001209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1567576914001209"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2014.03.017","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A monoclonal antibody ameliorates local inflammation and osteoporosis by targeting TNF-\u03b1 and RANKL","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2014.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}